DMT310-009 Topical in the Treatment of Acne Vulgaris

Completed · Phase 3 · Has a placebo group

Conditions studied: Acne Vulgaris

In brief

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris

Key facts

Study ID

NCT06090721

Run by

Dermata Therapeutics

People needed

520

Starts

2023-12-08

Expected to finish

2025-04-30

Last updated by the study team

2025-08-22

Who can join

Age: 9 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient sex at birth, male or non-pregnant female at least 9 years of age
• Clinical diagnosis of moderate to severe acne vulgaris as determined by:
• Investigator's Global Assessment (IGA) at Randomization; Patient has at least 20 inflammatory lesions and at least 20 noninflammatory lesions on the face
• Patient is willing to apply the Investigational Product as directed
• Patient is willing and able to comply with the protocol

You may not qualify if…

• Patient is pregnant or planning to become pregnant
• Patient is taking a topical therapy on the face which may affect the patient's acne

Where it is running

• Center for Dermatology Clinical Research, Inc. — Freemont, California, United States
• DermResearch — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.